NCT03088540 · OUTCOME

Maximum Plasma Concentration (Cmax) of Cemiplimab in Serum

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: mg/L
Interval / dispersion: Standard Deviation
Time frame: Up to 73.5 months

Analysis population: The PKAS included all randomized participants (SAF) who received cemiplimab and who had at least 1 non-missing cemiplimab concentration following the first dose of cemiplimab up to the end of the study.

Groups in this outcome

Cemiplimab

Participants received cemiplimab monotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cemiplimab	202

Reported measurements

Source class 1

Values in mg/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Cemiplimab	184	101	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
101
value
184

denoms

counts
group Id
OG000
value
202
units
Participants

dispersion Type

Standard Deviation

groups

description
Participants received cemiplimab monotherapy
id
OG000
title
Cemiplimab

param Type

MEAN

population Description

The PKAS included all randomized participants (SAF) who received cemiplimab and who had at least 1 non-missing cemiplimab concentration following the first dose of cemiplimab up to the end of the study.

reporting Status

POSTED

time Frame

Up to 73.5 months

title

Maximum Plasma Concentration (Cmax) of Cemiplimab in Serum

type

SECONDARY

unit Of Measure

mg/L

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice